Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 8,375 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Not applicable Interventional

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

NCT00627276
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 23, 2026, 2:54 AM EDT
Withdrawn Early Phase 1 Interventional

A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer

NCT01694589
View directory record Official record
Conditions
Resectable Pancreatic Cancer
Interventions
LDE-225
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Not applicable Interventional Results available

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

NCT01529450
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
LDE225
Drug
Lead sponsor
Anne Chang
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 23, 2026, 2:54 AM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT00510484
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain

NCT03295747
View directory record Official record
Conditions
Abdominal Pain
Interventions
Peppermint oil
Drug
Lead sponsor
Robert Shulman, M.D.
Other
Eligibility
7 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01124708
View directory record Official record
Conditions
ADHD
Interventions
TC-5619-238, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Bradenton, Florida • Jacksonville, Florida • Lauderhill, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00255190
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
181
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 178 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

NCT02289690
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Veliparib, Carboplatin, Etoposide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

NCT02567682
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

NCT04424888
View directory record Official record
Conditions
Diabetes Type 2, Diabetes Mellitus
Interventions
WB-011, Placebo, Continuous Glucose Monitor
Other · Device
Lead sponsor
Pendulum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

NCT03512418
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders
Interventions
PrEPsteps, Digital pill, Truvada
Behavioral · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boylston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

NCT04660890
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Not applicable Interventional

Probiotics in Primary Care

NCT01254097
View directory record Official record
Conditions
Antibiotic Side Effect
Interventions
Probiotic
Dietary Supplement
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

NCT03222310
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ipatasertib, Itraconazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 23, 2026, 2:54 AM EDT
Recruiting Phase 3 Interventional

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

NCT06229210
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Interventions
Lumateperone
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
59
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

NCT00613223
View directory record Official record
Conditions
Gliosarcoma, Glioblastoma
Interventions
Vandetanib and Etoposide
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 23, 2026, 2:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

NCT07656727
View directory record Official record
Conditions
Obesity and Cardiovascular Risk
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102
Drug
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
16
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

NCT01478594
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Tivozanib, Bevacizumab, mFOLFOX6
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
27
States / cities
Gilbert, Arizona • Hot Springs, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

NCT02091960
View directory record Official record
Conditions
HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions
Enzalutamide, Trastuzumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
16
States / cities
Anaheim, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

NCT00618124
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Neoplasms
Interventions
SU011248; Capecitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Indianapolis, Indiana • Albuqurque, New Mexico • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 1 Interventional

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

NCT00628420
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-104, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Not applicable Interventional Results available

Evaluation of PillCam® Express Capsule Endoscopy Delivery System

NCT01088646
View directory record Official record
Conditions
Small Bowel Disease, Inflammatory Bowel Disease
Interventions
PillCam® Express Capsule Endoscopy Delivery System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
2 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Huntsville, Alabama • Montgomery, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 23, 2026, 2:54 AM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

NCT00359788
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Combivent (Ipratropium/Albuterol)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 23, 2026, 2:54 AM EDT